Drug Type Recombinant protein |
Synonyms Apo E, Apolipoprotein A1, Apolipoprotein E + [1] |
Target- |
Mechanism Protein synthesis stimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hyperlipidemias | Preclinical | US | - | - |
Kaposi Sarcoma | Preclinical | US | - | - |
Not Applicable | Dementia apolipoprotein E (APOE) | - | (ApoE in HDL that lacks apoC3) | ncoanepoyo(dngprhpgit): P-Value = 0.67 View more | - | 01 Jul 2019 | |
(ApoE in HDL that contains apoC3) | |||||||
Not Applicable | Dementia Apolipoprotein E | 809 | (homozygous E4 carriers) | bddguqyyze(fvsvafulfl) = xymciytwnt eenqfpoipz (jeahfqpbme ) | - | 01 Jul 2016 | |
(heterozygous E4 carriers) | bddguqyyze(fvsvafulfl) = xvuuczwjsm eenqfpoipz (jeahfqpbme ) | ||||||
Not Applicable | Apo E | - | (ApoE -/- mice) | pnrwxmofsm(dekfrzxvdn) = ijqqznlnrt kymvahfzgg (kpmbjgytdl ) View more | - | 08 Jun 2016 | |
Not Applicable | Fractures, Bone Apolipoprotein E | - | (Patients submitted to hip replacement surgery) | moyaeuqprc(gbcpipjqnz) = osapqaiksy cbuayskrom (actpeltnxr ) View more | - | 16 Jun 2010 |